Thymic CarcinomaNCT07179341
Survival Nomogram for Patients With Thymic Carcinoma
A study testing Thymectomy for thymic carcinoma in people with Thymic Carcinoma, run by Weijie Ye at 1 site in China.
Trial summary
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients. Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Thymic Carcinoma
- What is being tested?
- Thymectomy for thymic carcinoma
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 156 participants
- Where
- 1 siteChina
- Study dates
- 9 Jul 2024to 1 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
- Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
- Patients who accepted surgery should be followed up at least six months or reached the endpoint event.
Who cannot join
- The patient had two types of primary tumors concurrently including TC.
- The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
- The patient did not obtain a complete pathological report after surgery.
Trial locations and contacts
1 site in 1 country.
China1 site
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China
Guangzhou, Guangdong
About this study
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.
Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.
- Conditions
- Thymic Carcinoma
- Being tested
- Thymectomy for thymic carcinoma
- Medical subject headings
- Thymoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thymectomy for thymic carcinomaProcedure or surgery
Thymectomy for thymic cancer
| Study group | Role | What they receive |
|---|---|---|
| Training cohort | Active comparator | 156 patients diagnosed with TC accepting surgery Receives: Procedure: Thymectomy for thymic carcinoma |
| Validation cohort one | Placebo comparator | 80 patients range from June 1, 1996, to January 1, 2015 accepting surgery Receives: Procedure: Thymectomy for thymic carcinoma |
| Validation cohort two | Placebo comparator | 76 patients range from January 2, 2015, to July 1, 2023 accepting surgery Receives: Procedure: Thymectomy for thymic carcinoma |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival (OS) is the length of time a patient lives after a diagnosis or the start of treatment for a disease, such as cancer
Measured: From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start9 Jul 2024
- Primary completion1 Jul 2025
- Study completion1 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thymic CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 156 participants (actual)
Sponsor and investigators
- Lead sponsor
- Weijie Ye
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Weijie Ye, Sun Yat-sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07179341
- Sponsor's protocol ID
- SL-B2024-411-01
- Status last verified
- Sep 2025
- First submitted
- 4 Sep 2025
- Last updated
- 17 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival Nomogram for Patients With Thymic Carcinoma
- ClinicalTrials.gov ID
- NCT07179341
- Acronym / sponsor ID
- SL-B2024-411-01
- Conditions
- Thymic Carcinoma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 156 participants (actual)
- Lead sponsor
- Weijie YeUniversity, hospital or other
- Study start
- 9 Jul 2024 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 1 Aug 2025 (actual)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.
Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Training cohort | Active comparator | Procedure: Thymectomy for thymic carcinoma156 patients diagnosed with TC accepting surgery |
| Validation cohort one | Placebo comparator | Procedure: Thymectomy for thymic carcinoma80 patients range from June 1, 1996, to January 1, 2015 accepting surgery |
| Validation cohort two | Placebo comparator | Procedure: Thymectomy for thymic carcinoma76 patients range from January 2, 2015, to July 1, 2023 accepting surgery |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
- Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
- Patients who accepted surgery should be followed up at least six months or reached the endpoint event.
Key exclusion criteria (3 listed)
- The patient had two types of primary tumors concurrently including TC.
- The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
- The patient did not obtain a complete pathological report after surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thymectomy for thymic carcinomaThymectomy for thymic cancer | Procedure or surgery | Training cohort, Validation cohort one, Validation cohort two |
Primary outcome
Overall survival
Time frame: From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months
Overall survival (OS) is the length of time a patient lives after a diagnosis or the start of treatment for a disease, such as cancer
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Thymic Carcinoma
Active, not recruitingPhase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma, Thymic Carcinoma
Active, not recruitingPhase 1
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
RecruitingObservational study
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Active, not recruitingPhase 2
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Thymic Epithelial Tumor, Recurrent Thymoma
RecruitingPhase 2
PT-112 in Subjects With Thymoma and Thymic Carcinoma
Thymic Epithelial Tumor, Recurrent Thymoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thymectomy for thymic carcinoma in people with Thymic Carcinoma, run by Weijie Ye at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025; AzTrials last refreshed its copy on 26 Oct 2026.